Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Kintara Therapeutics stock
Learn how to easily invest in Kintara Therapeutics stock.
Kintara Therapeutics Inc is a biotechnology business based in the US. Kintara Therapeutics shares (KTRA) are listed on the NASDAQ and all prices are listed in US Dollars. Kintara Therapeutics employs 4 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Kintara Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – KTRA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Kintara Therapeutics stock price (NASDAQ: KTRA)Use our graph to track the performance of KTRA stocks over time.
Kintara Therapeutics shares at a glance
|Latest market close||$0.40|
|52-week range||$0.42 - $3.35|
|50-day moving average||$0.67|
|200-day moving average||$1.26|
|Wall St. target price||$4.80|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.90|
Buy Kintara Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Kintara Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Kintara Therapeutics price performance over time
|1 week (2022-01-19)||-7.03%|
|1 month (2021-12-23)||-33.13%|
|3 months (2021-10-26)||-55.64%|
|6 months (2021-07-26)||-74.82%|
|1 year (2021-01-26)||-81.32%|
|2 years (2020-01-24)||-26.33%|
|3 years (2019-01-25)||0.4|
|5 years (2017-01-26)||4.15|
Kintara Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-67.76%|
|Return on equity TTM||-124.61%|
|Market capitalisation||$23.2 million|
TTM: trailing 12 months
Kintara Therapeutics share dividends
We're not expecting Kintara Therapeutics to pay a dividend over the next 12 months.
Have Kintara Therapeutics's shares ever split?
Kintara Therapeutics's shares were split on a 1:10 basis on 7 May 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kintara Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Kintara Therapeutics shares which in turn could have impacted Kintara Therapeutics's share price.
Kintara Therapeutics share price volatility
Over the last 12 months, Kintara Therapeutics's shares have ranged in value from as little as $0.416 up to $3.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kintara Therapeutics's is 1.589. This would suggest that Kintara Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Kintara Therapeutics overview
Kintara Therapeutics, Inc. , a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc.
Kintara Therapeutics in the news
Pre-market Movers: APM, BSFC, INPX, UPC, KAVL…
20 Stocks Moving in Tuesday's Pre-Market Session
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Frequently asked questionsWhat percentage of Kintara Therapeutics is owned by insiders or institutions?
Currently 1.105% of Kintara Therapeutics shares are held by insiders and 11.567% by institutions. How many people work for Kintara Therapeutics?
Latest data suggests 4 work at Kintara Therapeutics. When does the fiscal year end for Kintara Therapeutics?
Kintara Therapeutics's fiscal year ends in June. Where is Kintara Therapeutics based?
Kintara Therapeutics's address is: 12707 High Bluff Drive, San Diego, CA, United States, 92130 What is Kintara Therapeutics's ISIN number?
Kintara Therapeutics's international securities identification number is: US49720K1016
More guides on Finder
Walmart dives deep into the metaverse with crypto and NFTs
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
Dogecoin jumps 10% on word you can use it to buy Tesla merch
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
Thursday’s top U.S. stocks: Taiwan Semiconductor Manufacturing Company Ltd. (TSM ↑8.4%), Lam Research Corporation (LRCX ↑6.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Ask an Expert